Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 27, 2014

View Archived Issues

Novel association found for intracranial aneurysm susceptibility

Cardioxyl Pharmaceuticals begins first trial of CXL-1427

Roche discloses novel protein ligase inhibitors for cancer

Daiichi Sankyo discloses new agents for bacterial infections

Novel thrombin inhibitors prepared at Merck & Co.

Emory University patents new NMDA receptor modulators

Amgen divulges novel TRPM8 antagonists for migraine

Long-term analysis of a prognostic gene signature for breast cancer

NICE publishes final guidance recommending Eylea in England

Known cognition enhancer active in models of neuropathic pain

Application for approval of an oral disintegrating tablet formulation

Critical Outcome Technologies signs letter of intent with Portage Biotech for COTI-2

Treatment under way in phase IIb study of brilacidin for ABSSSI

Orexigen Therapeutics receives European CHMP questions on NB-32 MAA

Bexsero available in Canada

NICE final guidance recommends Pixuvri for relapsed/refractory B-cell NHL

Phase I study of tuberculosis vaccine DAR-901 opens

Dosing completed in phase II trial of Zoenasa for ulcerative colitis

Multifunctional polynitroxylated albumin for the early treatment of stroke

Chinese researchers synthesize new PI3Kdelta inhibitors

CytoVac initiates phase II study of ALECSAT for glioblastoma multiforme

InDex Pharmaceuticals closes new rights issue

NeRRe Therapeutics initiates phase II study of orvepitant for EGFR inhibitor-induced pruritus

Mast Therapeutics opens international enrollment in EPIC study of MST-188

Adocia reports preliminary results from phase I/II trial of BioChaperone Combo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 15, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance
BioWorld
It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...